ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1818

Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Philip Mease1, Taylor Blachley2, Jacqueline O’Brien2, Nicole Middaugh2, Greg Kricorian3, Scott Stryker3, David Collier4 and Alexis Ogdie-Beatty5, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3Amgen Inc., Thousand Oaks, CA, 4Amgen Inc., Simi Valley, CA, 5University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2021

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The burden of PsA and its chronic symptoms may have considerable impact on patient function and quality of life. Real-world research is limited on treatment response in PsA patients with different manifestations of PsA who are treated with a biologic DMARD. The objective of this study was to describe patient characteristics and disease outcomes within different PsA domains for patients initiating treatment with a TNF inhibitor (TNFi).

Methods: The CorEvitas PsA/Spondyloarthritis (SpA) Registry is a prospective, observational registry for patients with PsA or SpA under care of a rheumatologist. This study included adults with PsA who initiated treatment with a TNFi (adalimumab, etanercept, certolizumab pegol, infliximab, golimumab) from January 2013‒January 2020. We present unadjusted change in disease activity and patient-reported measures from baseline to 6 months for each PsA domain (enthesitis, dactylitis, peripheral arthritis, oligoarthritis, axial PsA disease, nail psoriasis, any skin disease, and moderate/high skin disease). We examined median time to therapy discontinuation and proportions of patients persistent on TNFi at 6, 12, and 24 months.

Results: A total of 631 patients with PsA initiated TNFi treatment. Peripheral arthritis (85%), skin disease (81%), and nail psoriasis (56%) were the most common PsA manifestations (Table 1). Most patients were receiving first- or second-line therapy (73%) (Table 1). At 6 months, improvements were observed for the overall population of TNFi initiators and within the subgroups defined by PsA domains (Table 2). Mean change from baseline in scores for Physician Global Assessment of Disease Activity (100-point VAS) ranged from −11.2 in patients with oligoarthritis to −18.8 in patients with dactylitis (Table 2). Similar patterns of improvement were seen in a subanalysis of patients treated with etanercept.

Among the overall population of patients who were not in minimal disease activity (MDA) at baseline, 25.8% achieved MDA at 6 months. Among the subtypes, the proportion of patients achieving MDA ranged from 19.5% in patients with axial PsA to 34.1% in patients with dactylitis (Table 2). Persistency at 6, 12, and 24 months for patients treated with a TNFi was 0.75, 0.57, and 0.39, respectively, and was similar across subgroups of patients with PsA manifestations (Table 3). Time to discontinuation was shortest in patients with enthesitis and axial PsA (12 and 13 months, respectively) and longest in those with oligoarthritis (20 months) (Table 3).

Conclusion: This analysis highlights the heterogeneity in presentation of PsA domains. In this real-world population, improvement was seen across all PsA domains after initiation of TNFi treatment.


Disclosures: P. Mease, AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Celgene, 2, Boehringer Ingelheim, 2, Genentech, 2, 5, 6, Janssen, 2, 5, 6, Gilead Sciences, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 6, GSK, 2; T. Blachley, CorEvitas, 3; J. O’Brien, CorEvitas, LLC, 3; N. Middaugh, CorEvitas, LLC, 3; G. Kricorian, Amgen Inc., 3, 11; S. Stryker, Amgen Inc, 3; D. Collier, Amgen Inc., 3, 11; A. Ogdie-Beatty, AbbVie, 2, Amgen, 2, 5, BMS, 2, Celgene, 2, CorEvitas (formerly Corrona), 2, Janssen, 2, Eli Lilly, 2, Novartis, 2, Pfizer, 2, UCB, 2, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 5, Rheumatology Research Foundation, 5, National Psoriasis Foundation, 5, Pfizer (to University of Pennsylvania), 5, AbbVie (to University of Pennsylvania), 5, Novartis (to University of Pennsylvania), 5, Gilead, 2.

To cite this abstract in AMA style:

Mease P, Blachley T, O’Brien J, Middaugh N, Kricorian G, Stryker S, Collier D, Ogdie-Beatty A. Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/real-world-efficacy-of-tnf-inhibitors-for-treatment-of-psoriatic-arthritis-by-disease-domains-6-month-findings-from-the-corevitas-psoriatic-arthritis-spondyloarthritis-registry/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-efficacy-of-tnf-inhibitors-for-treatment-of-psoriatic-arthritis-by-disease-domains-6-month-findings-from-the-corevitas-psoriatic-arthritis-spondyloarthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences